The OJC Episode 29: Neoadjuvant Therapy in Melanoma with Georgina Long

Pinterest LinkedIn Tumblr +

Exploring the clinical benefit of integrative genomic profiling, clinical trial eligibility criteria, contemporary oncology randomised clinical trials from low/middle-income vs high-income countries and much more. Plus an interview with Professor Georgina Long AO on pathological response and survival with neoadjuvant therapy in melanoma.

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 29 in our series The Oncology Journal Club.

This week’s episode is in our usual format featuring some fascinating papers, quirky quick bites and an MBS Update. Hans also interviews Professor Georgina Long on a recent publication in Nature Medicine on pathological response and survival with neoadjuvant therapy in melanoma – it’s a very passionate and engaging interview so this is a must-listen segment.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.

This Week’s Papers:

  1. Cobain EF, Wu Y, Vats P, et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncol. Published online February 25, 2021. doi:10.1001/jamaoncol.2020.7987 Access online here.
  2. Osarogiagbon, R.U., et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res February 9 2021 DOI: 10.1158/1078-0432.CCR-20-3854. Access online here.

This Week’s Interview:

  1. Menzies, A.M., et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 27, 301–309 (2021). Access online here.

This Week’s Quick Bites:

  1. Hanna NH, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2021 Feb 16:JCO2003570. doi: 10.1200/JCO.20.03570. Epub ahead of print. PMID: 33591844. Access online here.
  2. Drago, J.Z et al. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol (2021). Access online here.
  3. Johnson, Sonali et al. The World Cancer Declaration: time to consolidate wins and work towards 2025. The Lancet Oncology, Volume 22, Issue 3, 296 – 298. Access online here.
  4. Wells JC, Sharma S, Del Paggio JC, et al. An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncol. Published online January 28, 2021. doi:10.1001/jamaoncol.2020.7478 Access online here.
  5. Szomszor, M. et al. Interpreting Bibliometric Data. Res. Metr. Anal., 09 February 2021. Access online here.
  6. Patil V.M, et al. Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial, JNCI: Journal of the National Cancer Institute, 2021; Access online here.

MBS Update:

Twitter Account of the Week:
Dr Steve Martin AKA Balazs Halmos: @DrSteveMartin

Other Episodes Mentioned:

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen


Professor Georgina Long AO

Georgina Long

Professor Georgina Long AO, BSc PhD MBBS FRACP FAHMS, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.

In recognition of her ground-breaking research and work, Professor Long was appointed as an Officer of the Order of Australia (2020) and has received several awards, including the Research Australia, GSK Research Excellence Award (2018) and prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). Her H index is 103 and in February 2021 she was ranked the world’s 4th, and Australia’s 1st melanoma expert in all fields and discipline (

You can find Georgina on Twitter: @ProfGLongMIA

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Georgina Long AO and Graham Knowles.


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.